Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...
Zacks Investment Research on MSN23h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateNovo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Public-facing conversation regarding breast cancer is grounded in historical gender bias and is an example of the disparities in healthcare that women continue to face.
In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback